{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+-+Small+Cell+Lung+Cancer+NSCLC&page=2", "query": { "condition": "Non - Small Cell Lung Cancer NSCLC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+-+Small+Cell+Lung+Cancer+NSCLC&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T05:48:47.627Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00707252", "title": "Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Polyphenon E", "type": "DRUG" }, { "name": "Tarceva", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Louisiana State University Health Sciences Center Shreveport", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2008-01", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2015-04-21", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 1, "location_summary": "Shreveport, Louisiana", "locations": [ { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00707252" }, { "nct_id": "NCT00066885", "title": "Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "calcitriol + docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novacea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2003-06", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2007-05-07", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 11, "location_summary": "Berkeley, California • Vallejo, California • Denver, Colorado + 8 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Albany", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066885" }, { "nct_id": "NCT00823732", "title": "Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "end-of-life treatment/management", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2008-10", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00823732" }, { "nct_id": "NCT00482014", "title": "A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "pemetrexed", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2007-05", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2012-11-27", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 9, "location_summary": "Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Burlington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00482014" }, { "nct_id": "NCT02513667", "title": "Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ALK-positive Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Stereotactic ablative body radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-11", "completion_date": "2021-05-29", "has_results": true, "last_update_posted_date": "2023-02-03", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02513667" }, { "nct_id": "NCT04367311", "title": "Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nasser Hanna", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2020-05-22", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 9, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Berkeley Heights, New Jersey + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Berkeley Heights", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04367311" }, { "nct_id": "NCT07382726", "title": "Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Iza-bren", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-07-01", "completion_date": "2029-12-24", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07382726" }, { "nct_id": "NCT06105021", "title": "Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Solid Tumor", "KRAS G12V" ], "interventions": [ { "name": "AFNT-211", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affini-T Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-03-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06105021" }, { "nct_id": "NCT05215340", "title": "Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Datopotamab Deruxtecan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 740, "start_date": "2022-03-04", "completion_date": "2032-03-04", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 31, "location_summary": "Chandler, Arizona • Los Angeles, California • Santa Barbara, California + 19 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05215340" }, { "nct_id": "NCT02750215", "title": "A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Non-small Cell Neoplasm of Lung Stage IV" ], "interventions": [ { "name": "Capmatinib (INC280)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-05", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-07-22T05:48:47.627Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02750215" } ] }